Heart failure & cardiomyopathies
Heart Failure with Preserved Ejection Fraction, Red Cell Distribution Width, and Sacubitril/Valsartan
Authors' conclusion
RDW, a routinely available and inexpensive biomarker, provides incremental prognostic information when added to established predictors. Compared with valsartan, sacubitril/valsartan led to a small reduction in RDW.
Study context
- Population
- Heart failure (HF) with LVEF ≥45%, structural heart disease and elevated NT-proBNP (PARAGON-HF)
- Comparison
- RDW quartiles and outcomes; sacubitril/valsartan vs valsartan on RDW
- Primary endpoint
- Composite of:
- Total HF hospitalizations
- CV deaths
Primary result
As reported in the abstract
Each group vs quartile 1Rate ratio (95% CI)
Quartile 2
1.03(0.83–1.28)
Quartile 3
1.25(1.01–1.54)
Quartile 4
1.70(1.39–2.08)
- Median RDW at randomization
- 14.1% (IQR 13.5-15.0%)
Secondary outcomes
| Outcome | Mean change (95% CI) | |
|---|---|---|
| Change in RDW, sacubitril/valsartanvs valsartan · 48 weeks | −0.09 (−0.15 to −0.02) | |
| −0.2−0.100.1Difference (linear scale) |
Secondary outcomes incl. CV and all-cause death, by RDW
- Association with higher RDW seen for each secondary outcome
Treatment effect by baseline RDW
- Effect of sacubitril/valsartan vs valsartan not significantly modified by RDW at randomization
Original publication
Heart Failure with Preserved Ejection Fraction, Red Cell Distribution Width, and Sacubitril/Valsartan. ESC Heart Fail. Published 9 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →